Erectile dysfunction (ED) is the inability to achieve and maintain an erection sufficient to permit satisfactory sexual intercourse. Affecting 150 million men worldwide, ED is growing rapidly, and its prevalence is expected to double to greater than 300 million men worldwide over the next 20 years. According to data extrapolated from the Massachusetts Male Aging Study, the incidence of ED is increasing at an astronomical rate, with an expected incidence of over 600,000 new cases per year in white men aged 40 to 69 alone.
Despite its growing incidence (partly a result of the sexual awakening stimulated by the new pharmacologic therapies), ED remains under-diagnosed, with millions of men worldwide never seeking medical attention because of the sensitivity of the issue.
Data from an ongoing trial reveals that our patented NO technology can improve erectile function in patients taking a low dose PDE5 inhibitor that otherwise experienced an unsatisfactory erection with the PDE5 inhibitor alone.